权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NCTN - Network Lead Academic Participating Site: USC

NCTN - 网络领导学术参与站点：USC

基本信息

批准号：
9894739
负责人：
Anthony Boutros El-Khoueiry
金额：
$ 46.49万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-17 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9894739
关键词：
Advisory Committees Area Award Biological Blood Cell physiology Cells Cholangiocarcinoma Classification Clinical Clinical Research Clinical Trials Clinical Trials Design Collection Conceptions Correlative Study Dedications Development Drug Kinetics Elderly Enrollment Ensure Evaluation Freezing Functional Imaging Funding Grant Infrastructure Investigation K-Series Research Career Programs Laboratories Lead Leadership Maintenance Malignant Neoplasms Malignant neoplasm of prostate Malignant neoplasm of urinary bladder Mentors Methodology Minority Recruitment Modification Molecular Molecular Biology Molecular Profiling Molecular Target Monitor National Clinical Trials Network Normal tissue morphology Pathway interactions Patients Pharmaceutical Preparations Pharmacodynamics Pharmacology Pharmacology Study Play Positioning Attribute Recording of previous events Regimen Research Activity Research Design Research Infrastructure Research Personnel Resistance Resources Role Safety Sampling Site Southwest Oncology Group Standardization Structure Technology Testing Therapeutic Trials Toxic effect Training Translations Treatment Effectiveness Treatment Protocols Tumor Tissue University of Southern California Norris Cancer Center Variant anatomic imaging base biomarker development biomarker evaluation biomedical referral center cancer therapy clinical development data acquisition design drug development ethnic minority population experience genetic signature individual patient innovation member metastatic colorectal molecular diagnostics molecular subtypes named group neoplastic cell new technology new therapeutic target novel novel anticancer drug organizational structure patient population predicting response rare cancer recruit resistance mechanism response targeted agent translational study treatment strategy tumor

项目摘要

ABSTRACT The USC Norris Comprehensive Cancer Center first participated in the research activities of SWOG in 1987 and was initially funded in 1992. This five-year grant cycle has had increased administrative and academic participation, with maintenance of high clinical and correlative trial entry, commensurate with available SWOG funding and added resources from USC. The major emphases of the USC team are (a) to provide leadership across the NTCN to design and efficiently perform clinical trials evaluating the safety and efficacy of novel regimens or modifications of existing regimens; (b) to provide leadership in biomarker development and in integration of new technologies into NCTN trials, taking advantage of a systematic approach to collection, processing, and storage of blood, normal tissue, fresh or frozen tumor tissue, and other relevant biologic samples for molecular and pharmacologic studies; and (c) to evaluate cancer treatment regimens in special patient populations, such as rare cancers, the elderly and ethnic minorities. USC investigators have not only contributed extensively to SWOG trials but have demonstrated administrative/academic leadership, facilitating the translation of specific themes of investigation to SWOG. Recent NCTN trials such as SWOG/ALLIANCE 80405 and S1401 characterizing metastatic colorectal and prostate cancer has significant increased the understanding of molecular subtyping and characterization of both cancers integrating cutting edge technologies including NGS testing and single cell molecular classification. USC UG1 members are playing an active role in NCI task forces and steering committees. As part of its dedication to cancer clinical research, USC has been successful in mentoring young investigators through the UM1 Career Development Awards, Project Team Memberships and SWOG Young Investigator Awards. USC has expanded its institutional training and mentoring capabilities. Lastly, as a Network Lead Academic Participating Site, USC will continue to bring unique strengths to the NCI National Clinical Trials Network thanks to its strength in recruitment of minorities to clinical trials, accrual to rare cancers such as biliary and bladder cancers, and a well- developed clinical research infrastructure.

摘要